Das Gesundheitswesen , Thieme Verlag Heft 4-2021, Jahrgang 83) ISSN 1439-4421 Seite(n) 282 bis 290 DOI: 10.1055/a-1399-9166 CareLit-Dokument-Nr: 318600 |
|
Zusammenfassung Fragestellung Chronische Erkrankungen, wie z. B. angeborene Blutungsneigungen (IBD: Inherited Bleeding Disorders), gehen häufig mit einem erhöhten Versorgungsaufwand einher. Maßnahmen zur Eindämmung der COVID-19 Pandemie, inklusive Isolation und Triageierung, haben zu Einschränkungen in der Krankenversorgung von chronisch kranken Patienten geführt. Ziel der vorliegenden Arbeit ist es, die Auswirkungen der COVID-19 Pandemie auf die Krankenversorgung von IBD-Patienten zu untersuchen. Methodik In dieser multizentrischen Querschnittsstudie zur Bewertung der Auswirkungen von COVID-19 auf die psychische Gesundheit und Versorgungsqualität von Patienten mit angeborener Blutungsneigung wurde ein ad-hoc Fragebogen an 586 Patienten/Eltern von Kindern mit Hämophilie A, B oder von Willebrand Syndrom Typ 3 verschickt. Neben demografischen und klinischen Daten wurden IBD Patienten zu ihren Gedanken, Sorgen und Erfahrungen in Bezug auf ihre medizinische Versorgung während der COVID-19 Pandemie befragt. Unterschiede zwischen klinischen Subgruppen wurden berechnet. Ergebnisse Signifikante Unterschiede zeigten sich zwischen Subgruppen (Schweregrad, Art der Therapie, Produktklasse, Komorbiditäten) bezüglich Übertragung von COVID-19 durch Plasmaprodukte, Auswirkungen COVID-19 positiver Testergebnisse, Angst COVID-19 zu bekommen, verzögerter Medikamentenversorgung und Physiotherapiebehandlung. Diskussion Die medizinische Versorgung von IBD-Patienten, die eine kontinuierliche Versorgung mit lebensnotwendigen Medikamenten benötigen, stellt in Pandemiezeiten eine besondere Herausforderung dar. Daher sollten Sorgen und Ängste von IBD-Patienten ernst genommen und innovative Kommunikationswege zur Aufrechterhaltung von Therapiestandards und Versorgungsqualität etabliert werden. Abstract Background and Objectives Chronic diseases, such as inherited bleeding disorders (IBD) are often associated with high costs of medical care. COVID-19 containment measures, including isolation and triage, led to restrictions in the health care of chronically ill patients. The aim of the present study was to investigate the effects of the COVID-19 pandemic on the health care of IBD patients. Methods In this multicentre cross-sectional study to evaluate the effects of COVID-19 on the mental health and quality of care of patients with inherited bleeding disorder, an ad hoc questionnaire was sent to 586 patients/parents of children with haemophilia A, B or von Willebrand syndrome type 3. In addition to demographic and clinical data, patients/parents of patients with inherited bleeding disorders were asked about their thoughts, concerns and experiences regarding their medical care during the COVID-19 pandemic. Differences between clinical subgroups were calculated. Results Significant differences were found between subgroups (severity, type of therapy, product class, comorbidities) with regard to the transmission of COVID-19 through plasma products, the effects of COVID-19 positive test results, fear of getting COVID-19, delayed drug supply and physiotherapy treatment. Discussion The medical care of patients with inherited bleeding disorders, who need a continuous supply of essential drugs, is a particular challenge in times of pandemics. Therefore, worries and fears of IBD patients should be taken seriously and innovative communication channels established to maintain therapy standards and quality of care. Schlüsselwörter Sars-CoV-2 - Covid-19 Pandemie - Hämophilie - Medizinische Versorgung - Patientenerfahrungen Key words Sars-CoV2 - Covid-19 pandemic - Haemophilia - medical care - patient experience 08 April 2021 © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany Literatur 1 Leebeek FWG, Eikenboom JCJ. Von Willebrand’s Disease. The New England journal of medicine 2017; 376: 701-702 CrossrefPubMedGoogle Scholar 2 Mannucci PM, Tuddenham EG. The hemophilias – from royal genes to gene therapy. The New England journal of medicine 2001; 344: 1773-1779 CrossrefPubMedGoogle Scholar 3 Wiley RE, Khoury CP, Snihur AWK. et al. From the voices of people with haemophilia A and their caregivers: Challenges with current treatment, their impact on quality of life and desired improvements in future therapies. Haemophilia 2019; 25: 433-440 CrossrefPubMedGoogle Scholar 4 Miesbach W, Schwäble J, Müller MM. et al. Treatment Options in Hemophilia. Dtsch Arztebl Int 2019; 116: 791-798 PubMedGoogle Scholar 5 Auerswald G, Dolan G, Duffy A. et al. Pain and pain management in haemophilia. Blood Coagul Fibrinolysis 2016; 27: 845-854 CrossrefPubMedGoogle Scholar 6 Manco-Johnson MJ, Soucie JM, Gill JC. Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project. Blood 2017; 129: 2368-2374 CrossrefPubMedGoogle Scholar 7 Souza JC, Pettengill EC, Pettengill CA. Psychosocial Aspects of Quarantine, Social Isolation and Social Distance. Psychology 2020; 11: 1200-1214 CrossrefPubMedGoogle Scholar 8 Bundesministerium für Gesundheit. Coronavirus Sars-CoV2-2: Chronik der bisherigen Maßnahmen. https://bundesgesundheitsministerium.de/coronavirus/chronik-coronavirus.html (Letzter Zugriff 09.09.2020) 9 Kong HE, Grant-Kels JM, Stoff BK. Applying the ethical principles of resource allocation to drugs in limited supply during a public health crisis. Journal of the American Academy of Dermatology. 2020 83: 170–171 Google Scholar 10 Hermans C, Lambert C. Impact of the COVID-19 pandemic on therapeutic choices in thrombosis-hemostasis. J Thromb Haemost 2020; 18: 1794-5 CrossrefPubMedGoogle Scholar 11 Bhidayasiri R, Virameteekul S, Kim J-M. et al. COVID-19: An early review of its global impact and considerations for Parkinson’s disease patient care. Journal of movement disorders 2020; 13: 105-114 CrossrefPubMedGoogle Scholar 12 Bao Y, Sun Y, Meng S. et al. 2019-nCoV epidemic: address mental health care to empower society. Lancet 2020; 395: e37-e38 CrossrefPubMedGoogle Scholar 13 Rajkumar RP. COVID-19 and mental health: A review of the existing literature. Asian journal of psychiatry. 2020: 52:102066 Google Scholar 14 Elovainio M, Hakulinen C, Pulkki-Råback L. et al. Contribution of risk factors to excess mortality in isolated and lonely individuals: an analysis of data from the UK Biobank cohort study. The Lancet. Public health 2017; 2: e260-e266 PubMedGoogle Scholar 15 Valentino LA, Skinner MW, Pipe S. The role of telemedicine in the delivery of healthcare in the COVID-19 Pandemic. Haemophilia. 2020 26: e230–e231 Google Scholar 16 Hermans C, Weill A, Pierce GF. The COVID-19 pandemic: New global challenges for the haemophilia community. Haemophilia 2020; 26: 371-372 CrossrefPubMedGoogle Scholar 17 von Mackensen S, Halimeh S, Siebert M. et al. Impact of COVID-19 pandemic on mental health of patients with inherited bleeding disorders in Germany. Haemophilia 2020; 26: e272-e281 PubMedGoogle Scholar 18 Bundesinstitut für Risikobewertung. BfR-Corona-Monitor vom 21. April. Available at https://www.bfr.bund.de/cm/343/200421-bfr-corona-monitor.pdf. Accessed June 05, 2020 19 Bundesinstitut für Risikobewertung. BfR-Corona-Monitor vom 28. April. Available at https://www.bfr.bund.de/cm/343/200428-bfr-corona-monitor.pdf. Accessed June 05, 2020 20 Mitteldeutscher Rundfunk. Corona-Ausbreitung macht Menschen aktuell wenig Angst Available at https://www.mde/nachrichten/mitmachen/mdrfragt/umfrage-ergebnis-corona-virus-100.html Accessed June 05, 2020 21 Dong Y, Peng CY. Principled missing data methods for researchers. Springerplus 2013; 2: 222 CrossrefPubMedGoogle Scholar 22 Hazra A, Gogtay N. Biostatistics Series Module 4: Comparing groups – categorical variables. Indian journal of dermatology 2016; 61: 385-392 CrossrefPubMedGoogle Scholar 23 du Prel JB, Hommel G, Röhrig B. et al. Confidence interval or p-value? Part 4 of a series on evaluation of scientific publications [Konfidenzintervall oder p-Wert? Teil 4 der Serie zur Bewertung wissenschaftlicher Publikationen]. Dtsch Arztebl Int 2009; 106: 335-339 PubMedGoogle Scholar 24 Baruch Y. Response rate in academic studies – A comparative analysis. Human Relations 1999; 52: 421-438 CrossrefPubMedGoogle Scholar 25 Paul-Ehrlich-Institut – DHR – Daten https://www.pei.de/DE/regulation/melden/dhr/dhr-node.html (Letzter Zugriff 17.07.2020) 26 Napolitano M, Mansueto MF, Sirocchi D. et al. Emotions and Opinions of Adult Patients with Haemophilia During the COVID-19 (Coronavirus Disease 2019) Pandemic Caused by SARS-CoV-2: A Monocentric Survey. Patient Prefer Adherence 2020; 14: 1145-1147 CrossrefPubMedGoogle Scholar 27 Härter M, Bremer D, Scherer M. et al. Auswirkungen der COVID-19-Pandemie auf die klinische Versorgung, Arbeitsprozesse und Mitarbeitenden in der Universitätsmedizin: Ergebnisse einer Interviewstudie am UKE. Gesundheitswesen. 2020 Google Scholar 28 Lurie N, Carr BG. The role of telehealth in the medical response to disasters. JAMA internal medicine 2018; 178: 745-746 CrossrefPubMedGoogle Scholar 29 EAHAD – EHC. EAHAD–EHC: COVID-19 Joint Statement. Available at http://eahad.org/eahad-ehc-covid-19-joint-statement/ (Letzter Zugriff 05.05.2020.) 30 Adhikari SP, Shrestha P, Dev R.. Feasibility and Effectiveness of Telephone-Based Telephysiotherapy for Treatment of Pain in Low-Resource Setting: A Retrospective Pre-Post Design. Pain Res Manag. 2020 2741278. Google Scholar 31 Negrini S, Donzelli S, Negrini A. et al. Zaina F. Feasibility and Acceptability of Telemedicine to Substitute Outpatient Rehabilitation Services in the COVID-19 Emergency in Italy: An Observational Everyday Clinical-Life Study. Arch Phys Med Rehabil. 2020; DOI: 10.1:2027–2032. PubMedGoogle Scholar 32 De La Corte-Rodriguez H, Rodriguez-Merchan EC, Alvarez-Roman MT. et al. Intra-articular injections in people with haemophilia in the COVID-19 era. Haemophilia. 2020 26 e250–e252 Google Scholar 33 Hermans C, Lambert C, Sogorb A. et al. In-hospital management of persons with haemophilia and COVID-19: practical guidance. Haemophilia. 2020 26: 768–772 Google Scholar 34 Zanon E, Pasca S, Campello E. et al. How haemophilia A impacts severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) treatment: a case report. J Thromb Thrombolysis. 2020 50. 795-798 Google Scholar 35 Mannucci PM. Viral safety of coagulation factor concentrates: memoirs from an insider. J Thromb Haemost 2018; 16: 630-633 CrossrefPubMedGoogle Scholar 36 Gavin B, Lyne J, McNicholas F. Mental health and the COVID-19 pandemic: looking back and moving forward. Irish journal of psychological medicine. 2020 37. 247-249 Google Scholar 37 Dorgalaleh A, Dabbagh A, Tabibian S. et al. Patients with Congenital Bleeding Disorders Appear to be Less Severely Affected by SARS-CoV-2: Is Inherited Hypocoagulability Overcoming Acquired Hypercoagulability of Coronavirus Disease 2019 (COVID-19)?. Semin Thromb Hemost. 2020 46: 853–855 Google Scholar
{{detailinfo.data.api.data.document[0].apa}}
{{detailinfo.data.api.data.document[0].vancouver}}
{{detailinfo.data.api.data.document[0].harvard}}